Safety and immunogenicity of two formulations of a hexavalent diphtheria-tetanus-acellular pertussis-inactivated poliovirus-Haemophilus influenzae conjugate-hepatitis B vaccine in 15 to 18-month-old children.

Human vaccines

Volumn 1, Issue 6, 2005, Pages 245-250

  Halperin, Scott A ^a   Langley, Joanne M ^a   Hesley, Teresa M ^a   Zappacosta, Pamela S ^a   Radley, David ^a   Smith, Bruce ^a   Hoffenbach, Agnes ^a   Boslego, John ^a   Silber, Jeffrey L ^a  

^a IWK HEALTH CENTRE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIUM ANTIBODY; DIPHTHERIA PERTUSSIS TETANUS VACCINE; HAEMOPHILUS VACCINE; HEPATITIS B VACCINE; POLIOMYELITIS VACCINE; VACCINE; VIRUS ANTIBODY;

ARTICLE; BLOOD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HUMAN; IMMUNOLOGY; INFANT; MALE; PHASE 1 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; VACCINATION;

ANTIBODIES, BACTERIAL; ANTIBODIES, VIRAL; DIPHTHERIA-TETANUS-PERTUSSIS VACCINE; FEMALE; HAEMOPHILUS VACCINES; HEPATITIS B VACCINES; HUMANS; INFANT; MALE; POLIOVIRUS VACCINE, INACTIVATED; VACCINATION; VACCINES, CONJUGATE;

EID: 33750604613     PISSN: 15548600     EISSN: None     Source Type: Journal    
DOI: 10.4161/hv.1.6.2377     Document Type: Article

References (0)